Company intelligence / Profile preview
mAbxience
León, León, Spainmabxience.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
mAbxience has developed and commercialized two biosimilar medicines in oncology—rituximab and bevacizumab—available globally. The company maintains a robust pipeline targeting oncology, hematology, osteoporosis, pediatrics, and rare diseases like Fabry disease through partnerships. Their products meet stringent global regulatory standards.
- Therapeutic areas
- ImmunologyEndocrinologyHematologyOtherOncologyRare Diseases
- Modalities
- Monoclonal antibodies (mAbs)BiosimilarsOther biologics
- Industry
- Biotech
02
Drug pipeline
4 assets3 more assets in the full pipeline.
03
Partnerships
Over thirty global/regional partners for B2B commercialization/distribution worldwide.Strategic manufacturing agreement with Biosidus for Agalsidase Beta/Fabrazyme biosimilar production.
Beyond the preview
Go deeper on mAbxience.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on mAbxience.